一项针对晚期肺癌患者的研究显示，早晨时段接受免疫化疗可显著延长生存时间。香港医学专家表示，这一发现为优化治疗时机提供了可能性，但需进一步研究。该研究由湖南癌症医院主导，并获香港中文大学医学系支持。
晚期肺癌患者若在上午时段接受免疫化疗，治疗效果更佳，一项新研究揭示了这一发现。该研究针对非小细胞肺癌患者，比较了不同时段的治疗效果，结果显示，上午3点前施用免疫化疗，几乎将从治疗开始到疾病进展的时间（无进展生存期）延长了一倍，同时将中位总生存期提高了近70%。
这项随机对照研究是首次证明晨间与午后输注免疫化疗的差异，由湖南癌症医院学者主导，并在《自然医学》杂志上发表。香港中文大学临床肿瘤学系主任、研究联合通讯作者莫树锦教授于周五表示：“这一发现极具鼓舞性，仅通过简单调整治疗时机，即可提升疗效并改善生存率，而无需额外成本给患者或医疗系统带来负担。”
莫教授强调，虽然结果令人振奋，但仍需更多研究来验证和推广这一优化策略。该研究为肺癌治疗带来了新希望，尤其是在免疫疗法日益重要的背景下。
由 AI 报道 AI 生成的图像 事实核查
Researchers at Karolinska Institutet report that using a reduced dose of ipilimumab together with nivolumab in immunotherapy for advanced malignant melanoma was associated with better tumor control and fewer serious side effects than the traditional full-dose combination. In a real-world study of nearly 400 patients with advanced, inoperable skin cancer, response rates and survival times were higher in the lower-dose group, according to results published in the Journal of the National Cancer Institute.
A randomized trial shows that administering cancer immunotherapy before 3pm can nearly double survival time for patients with non-small cell lung cancer. Researchers found significant benefits from aligning treatment with circadian rhythms during the initial cycles. This marks the strongest evidence yet for chronotherapy in oncology.
由 AI 报道
Scientists at Cold Spring Harbor Laboratory have found that breast cancer quickly disrupts the brain's internal clock in mice, flattening daily stress hormone cycles and impairing immune responses. Remarkably, restoring these rhythms in specific brain neurons shrank tumors without any drugs. The discovery highlights how early physiological imbalances may worsen cancer outcomes.
The US Food and Drug Administration has granted fast-track status to an innovative inhalable gene therapy for advanced lung cancer, following promising early trial results. Developed by Krystal Biotech, the treatment uses a modified virus to deliver immune-boosting genes directly to lung cells via inhalation. In initial tests, it shrank tumors in some patients and halted growth in others.
由 AI 报道 事实核查
Scientists at the Icahn School of Medicine at Mount Sinai report an experimental CAR T-cell strategy that targets tumor-associated macrophages—the immune cells many tumors use as a protective shield—rather than attacking cancer cells directly. In preclinical mouse models of metastatic ovarian and lung cancer, the approach reshaped the tumor microenvironment and extended survival, with some animals showing complete tumor clearance, according to a study published online January 22 in Cancer Cell.
Researchers at Cold Spring Harbor Laboratory have identified key proteins and protein complexes that help certain carcinomas shift their cellular identity and potentially evade treatment. Two new studies, focusing on pancreatic cancer and tuft cell lung cancer, highlight molecular structures that could become targets for more precise and selective therapies.
由 AI 报道 事实核查
Researchers at the Institut Pasteur and Inserm have developed a triple-drug strategy that induces necroptosis in malignant B cells, triggering a strong anti-tumor immune response in preclinical models of leukemia. By reprogramming how cancer cells die, the approach enabled complete leukemia elimination in animals and may offer a new avenue for treating B cell-related blood cancers, according to findings published in Science Advances.